Inogen, Inc.
HealthcareNASDAQ:INGN · NASDAQ Global Select
+$0.10 today
Vol 0.15M · Avg 0.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.8%
avg -5.6%
ROIC
-12.3%
avg -5.4%
ROA
-7.6%
avg -2.9%
Analysis
ROA is currently the strongest return metric at -7.6% versus its period average of -2.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin R. Smith | President, Chief Executive Officer & Director | $739,254.00 | — | 55 | $104,966.00 | 0.39% |
Jennifer Yi Boyer | Executive Vice President of Enterprise Enablement & Chief Human Resources Officer | $657,095.00 | — | 51 | $15,977.00 | 0.06% |
Michael J. Bourque | Advisor | $646,379.00 | — | 63 | $100,949.00 | 0.37% |
Grgoire Ramade | Executive Vice President & Chief Commercial Officer | $606,779.00 | — | 56 | $50,251.00 | 0.19% |
Kevin Smith | General Counsel, Secretary & Executive Vice President of Business Development | $588,236.00 | — | 55 | $104,966.00 | 0.39% |
Dominic Hulton | Chief Marketing Officer | — | — | — | — | — |
Naga Rameswamy | Chief Technology Officer | — | — | — | — | — |
Lorna Williams | Senior Vice President of Investor Relations | — | — | — | — | — |
Mary Wright | VP & Chief Accounting Officer | — | — | 39 | $104,966.00 | 0.39% |
Philip Corrin | Senior Vice President of Operations & Supply Chain | — | — | — | — | — |
Jason A. Richardson | CFO, Executive VP & Treasurer | — | — | 49 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$70,313.02
Net Sentiment
$70,313.02
Net selling
Most Active
Yi Boyer Jennifer M
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $70,313.02 over the last 12 months. That adds up to net selling of $70,313.02. Yi Boyer Jennifer M was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -7.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +48.5% | +7.6% (15yr)1 analysts |
| Net Income | N/A | N/A | +173.9% | -5.9% (15yr)1 analysts |
| EBIT | N/A | N/A | +162.8% | N/A1 analysts |
Analysis
Recent growth has been strongest in Net Income at +173.9% over three years. Forward estimates point to Revenue at +7.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Shoulder Innovations, Inc.
NYSE:SI
$387.80M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
Health Catalyst, Inc.
NASDAQ:HCAT
$136.70M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Solana Company
NASDAQ:HSDT
$89.92M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
Who manages INGN?
Inogen, Inc. (INGN) lists 11 active executives. The top listed executive is Michael J. Bourque, Advisor.
Are INGN insiders buying or selling?
Recent insider activity shows net selling of $2.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.